欧洲围术期静脉血栓栓塞预防指南:重症监护
该指南针对重症监护病房患者,在常规药物预防下静脉血栓栓塞仍占4%至15%,推荐全院统一预防方案(1B级),不推荐常规超声筛查深静脉血栓(1B级),危重患者优选低分子肝素而非低剂量肝素(1B级),并给出肾功能不全、肝功能障碍及肝素诱导血小板减少症的管理建议。
要点
- 推荐全院统一静脉血栓栓塞预防方案(1B级)。
- 危重患者优选低分子肝素而非低剂量肝素(1B级)。
- 疑似或确诊肝素诱导血小板减少症时停用所有肝素(1B级)。
核心结论
- 重症监护患者需全院统一静脉血栓栓塞预防方案,危重患者优选低分子肝素,不推荐常规超声筛查深静脉血栓。
研究设计与样本
- 欧洲麻醉学杂志发布的围术期静脉血栓栓塞预防指南,针对重症监护患者。
主要发现
- 常规药物预防下ICU患者静脉血栓栓塞发生率为4%至15%。
- 常规超声筛查深静脉血栓可能引发治疗性抗凝增加出血风险,且未证实减少临床显著血栓事件。
- 尚无前瞻性研究评估严重肝功能障碍危重患者深静脉血栓预防的有效性与安全性。
关键数值与推荐
- 推荐全院统一静脉血栓栓塞预防方案(1B级)。
- 不推荐常规超声筛查深静脉血栓(1B级)。
- 危重患者推荐低分子肝素优于低剂量肝素(1B级)。
- 严重肾功能不全危重患者建议低剂量肝素(2C级)、达肝素(2B级)或减量依诺肝素(2C级),可考虑监测抗Xa活性(2C级)。
- 不推荐常规使用下腔静脉滤器作为静脉血栓栓塞一级预防(1C级);疑似或确诊肝素诱导血小板减少症时停用所有肝素(1B级),推荐立即使用非肝素抗凝药而非仅停用肝素(1C级)。
临床怎么用
- ICU应建立并执行全院统一的静脉血栓栓塞预防方案。
- 危重患者药物预防优先选择低分子肝素,严重肾功能不全时调整药物或剂量。
- 不常规超声筛查深静脉血栓,疑似肝素诱导血小板减少症时立即停用肝素并换用非肝素抗凝药。
局限性
- 严重肝功能障碍危重患者缺乏前瞻性研究数据,药物预防需权衡出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
: Venous thromboembolism is a common and potentially life-threatening complication that occurs in 4 to 15% of patients admitted to ICUs despite the routine use of pharmacological prophylaxis. We therefore recommend an institution-wide protocol for the prevention of venous thromboembolism (Grade 1B). The routine use of ultrasonographic screening for deep vein thrombosis is not recommended when thromboprophylactic measures are in place (Grade 1B), as the detection of asymptomatic deep vein thrombosis may prompt therapeutic anticoagulation that may increase bleeding risk but has no proven reduction of clinically significant thrombotic events. In critically ill patients, we recommend pharmacological prophylaxis with low molecular weight heparin over low-dose heparin (Grade 1B). For critically ill patients with severe renal insufficiency, we suggest the use of low-dose heparin (Grade 2C), dalteparin (Grade 2B) or reduced doses of enoxaparin (Grade 2C). Monitoring of anti-Xa activity may be considered when low molecular weight heparin is used in these patients (Grade 2C). No study has prospectively evaluated the efficacy and safety of deep vein thrombosis prophylaxis in critically ill patients with severe liver dysfunction. Thus, the use of pharmacological prophylaxis in these patients should be carefully balanced against the risk of bleeding. For critically ill patients, we recommend against the routine use of inferior vena cava filters for the primary prevention of venous thromboembolism (Grade 1C). When the diagnosis of heparin-induced thrombocytopaenia is suspected or confirmed, all forms of heparin must be discontinued (Grade 1B). In these patients, immediate anticoagulation with a nonheparin anticoagulant rather than discontinuation of heparin alone is recommended (Grade 1C).
引用
- Duranteau J, Taccone FS, Verhamme P, et al. European guidelines on perioperative venous thromboembolism prophylaxis: Intensive care. Eur J Anaesthesiol. 2018. PMID: 29112545. doi:10.1097/EJA.0000000000000707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。